Company intelligence

Scribe Therapeutics

As of September 4, 2026, Scribe Therapeutics had a market capitalization of $542.77M (stockanalysis.com).

Clinical-stage biotech developing CRISPR-based gene-editing therapeutics using its proprietary CasX enzyme platform.

BiotechPublic · SCTXAlameda, California, USAFounded 2018Founders: Benjamin Oakes, Jennifer Doudna, Brett T. StaahlPublic companyWebsite ↗See connections →Compare with Braveheart Bio
Last verified Sep 4, 2026

Scribe Therapeutics at a glance

As of
Market cap
$542.77M[1]
September 2026
Lead investors
Andreessen Horowitz[2]
Series A · October 2020
Founded
2018[3]
Headquarters
Alameda, California, USA[4]
  1. [1] Market cap: stockanalysis.com, September 4, 2026
  2. [2] Lead investors: TechCrunch, October 6, 2020
  3. [3] Founded: TechCrunch (retrieved October 6, 2020)
  4. [4] Headquarters: Scribe Therapeutics (retrieved July 27, 2026)

What Scribe Therapeutics does

Scribe Therapeutics is a clinical-stage biotech in Alameda, California, that engineers in vivo CRISPR technologies aimed at preventing disease.[1] Its lead candidate, STX-1150, is designed to epigenetically silence the PCSK9 gene to lower LDL cholesterol without permanently altering DNA.[2] First-in-human data for STX-1150 are expected in the first half of 2027.[3],[2] Two preclinical programs target the LPA and APOC3 genes, with human trials planned for 2027 or 2028.[3],[4] Scribe has partnerships with Sanofi and Eli Lilly; the Sanofi deal, worth a potential $1 billion-plus, covers NK cell therapies for cancer.[5] Its shares began trading on the Nasdaq Global Market on July 24, 2026, under the ticker SCTX.[1] Including the underwriters' full option and a concurrent private placement of 500,000 shares to Sanofi, gross proceeds were about $155.51 million.[1],[5] Leerink Partners, Goldman Sachs, Guggenheim Securities and Wells Fargo Securities ran the offering.[1]

Leadership

  • It was founded by CRISPR co-discoverer Jennifer Doudna and her UC Berkeley collaborators Benjamin Oakes, Brett Staahl and David Savage.[6]

Is something wrong on this page?

Company Snapshot

Scribe Therapeutics is a biotech company, based in Alameda, California, USA, founded 2018 by Benjamin Oakes, Jennifer Doudna, Brett T. Staahl.

Recent changes

  1. Sep 4, 2026First reported market cap: $542.77M stockanalysis.com
  2. Jul 27, 2026First reported total funding: IPO gross proceeds ~$155.5M (incl. private placement) Scribe Therapeutics
  3. Jul 24, 2026Raised $129M BioPharma Dive
  4. Jul 24, 2026IPO $155.5M (incl. private placement) Scribe Therapeutics
  5. Jul 24, 2026Scribe Therapeutics Prices Upsized IPO With Sanofi Backing Pulse story
Earlier changes (6)
  1. Jul 23, 2026Scribe Therapeutics Soars In Rare Gene-Editing IPO Pulse story
  2. Jul 10, 2026Doudna-Founded Scribe Therapeutics Files S-1/A for Nasdaq IPO Pulse story
  3. Jul 2, 2026Scribe Therapeutics, Co-Founded by Nobel Laureate Jennifer Doudna, Files S-1 for Nasdaq IPO Pulse story
  4. Jul 2, 2026Scribe Therapeutics Files for $75M IPO to Test Early-Stage Biotech Appetite Pulse story
  5. Oct 6, 2020Raised $20M Series A TechCrunch
  6. Oct 6, 2020New investor: Andreessen Horowitz TechCrunch

Funding history

2 equity events · newest first · sources dated per row
DateRoundAmountValuationLead investorsSource
Jul 24, 2026Funding round$129M—
—
BioPharma Dive
Oct 6, 2020Series A$20M—TechCrunch

Equity only. “Equity raised” above sums the rounds with a dated, linked source; rumored rounds, tender offers and secondary sales are listed but not counted, and debt financing is listed separately.

Debt, IPO & other events

not counted in equity raised
DateEventAmountValuationInvestorsSource
Jul 24, 2026IPO$155.5M (incl. private placement)—Scribe Therapeutics

How Scribe Therapeutics has been funded

Andreessen Horowitz led its $20 million Series A in October 2020.[6] Scribe priced its IPO at $15 a share on July 23, 2026, the first IPO for a gene editing company since Metagenomi in February 2024.[3],[5],[1]

Investors

Latest Pulse

  1. The IPO Window Is Splitting Into Two Very Different TiersThis week's debuts split the 2026 IPO market sharply: differentiated biotech stories got double-digit pops, while mature, sponsor-backed consumer brands opened flat or down regardless of profitability.→
  2. Apnimed Soars 37% in Nasdaq Debut for Sleep Apnea PillApnimed shares jumped as much as 37.5% in their Nasdaq debut after the Phase 3 biotech priced its upsized IPO at $16 a share, raising $192 million to fund what could become the first FDA-approved pill for obstructive sleep apnea.→
  3. Apnimed Prices Upsized IPO at $16, Raises $192MApnimed priced an upsized IPO at $16 per share, raising $192 million ahead of its Nasdaq debut under ticker APMD, betting on the first potential FDA-approved pill for obstructive sleep apnea.→
  4. Why 2026's IPO Debuts Are Splitting Into Two TiersThis week's IPO calendar is splitting cleanly into two tiers -- AI-adjacent and clinical-stage biotech names popping double digits, while established consumer and franchise brands price cleanly but open flat or down, a divergence worth watching as the 2026 IPO window matures.→
  5. Reformation Opens Flat, Valued at $886M in NYSE DebutReformation opened flat at its $15 IPO price in its NYSE debut Thursday, valuing the Permira-backed sustainable fashion brand at $886.1 million after it raised $210.9 million pricing at the bottom of its range.→
  6. Goldman-Backed Attovia Sets Terms for $200M Nasdaq IPOAttovia Therapeutics set terms for a Nasdaq IPO, offering 12.5 million shares at $15-17 to raise up to $212.5 million, advancing its Phase 1 itch and eczema drug candidates toward a public listing under ticker ATTO.→
  7. Why Half Of 2026's IPO Class Trades Underwater203 companies have gone public on the NYSE or Nasdaq in 2026, but roughly half now trade below their offering price -- and Tuesday's SpaceX whipsaw shows exactly why scarcity-driven IPO pops keep failing to hold.→
  8. SpaceX Shares Whipsaw, Briefly Erase $1.2 TrillionSpaceX stock briefly fell more than 20% below its June IPO price on Tuesday, wiping out roughly $1.2 trillion in paper value before paring losses, as the thin public float that fueled its post-IPO pop now works in reverse.→
  9. Value Add Pulse Analysis: The IPO Hype Cycle Returns203 companies have gone public on the NYSE or Nasdaq in 2026, but roughly 49% now trade below their IPO price, exposing a widening gap between opening-day demand and durable public-market performance.→
  10. Why 2026's IPO Market Already Beat Goldman's BetA Value Add Pulse analysis of 2026's IPO market finds proceeds already tracking well ahead of Goldman Sachs's February forecast of $160 billion for the full year, driven by a handful of enormous AI-adjacent listings.→

Coverage Timeline

newest first
  1. Jul 24, 2026IPOScribe Therapeutics Prices Upsized IPO With Sanofi Backing$128.7M Raised→
  2. Jul 23, 2026IPOScribe Therapeutics Soars In Rare Gene-Editing IPO$128.7M IPO→
  3. Jul 10, 2026IPODoudna-Founded Scribe Therapeutics Files S-1/A for Nasdaq IPO$180M+ partnership payments→
  4. Jul 2, 2026IPOScribe Therapeutics, Co-Founded by Nobel Laureate Jennifer Doudna, Files S-1 for Nasdaq IPOS-1 filed→
  5. Jul 2, 2026IPOScribe Therapeutics Files for $75M IPO to Test Early-Stage Biotech AppetiteUp to $75M IPO→

All Coverage

IPO
Scribe Therapeutics Prices Upsized IPO With Sanofi Backing
IPO$128.7M Raised

Scribe Therapeutics Prices Upsized IPO With Sanofi Backing

Gene-editing biotech Scribe Therapeutics priced an upsized IPO at $15 per share, raising $128.7 million with Sanofi as a strategic anchor investor, the first gene-editing IPO in over two years.

IPO
Scribe Therapeutics Soars In Rare Gene-Editing IPO
IPO$128.7M IPO

Scribe Therapeutics Soars In Rare Gene-Editing IPO

Scribe Therapeutics priced an upsized $128.7 million IPO and surged in its Nasdaq debut, a rare early-stage listing for a gene-editing biotech in a market that has favored de-risked, later-stage companies.

IPO
Doudna-Founded Scribe Therapeutics Files S-1/A for Nasdaq IPO
Illustration for: Doudna-Founded Scribe Therapeutics Files S-1/A for Nasdaq IPO
IPO$180M+ partnership payments

Doudna-Founded Scribe Therapeutics Files S-1/A for Nasdaq IPO

Scribe Therapeutics, the CRISPR biotech co-founded by Nobel laureate Jennifer Doudna, amended its S-1 to list on Nasdaq under ticker SCTX, backed by more than $180 million in Sanofi and Eli Lilly partnership payments.

IPO
Scribe Therapeutics, Co-Founded by Nobel Laureate Jennifer Doudna, Files S-1 for Nasdaq IPO
Illustration for: Scribe Therapeutics, Co-Founded by Nobel Laureate Jennifer Doudna, Files S-1 for Nasdaq IPO
IPOS-1 filed

Scribe Therapeutics, Co-Founded by Nobel Laureate Jennifer Doudna, Files S-1 for Nasdaq IPO

Scribe Therapeutics filed its S-1 with the SEC on July 2, seeking to list on the Nasdaq Global Market under the ticker 'SCTX.' The clinical-stage biotech, co-founded by CRISPR pioneer and Nobel laureate Dr. Jennifer Doudna, has raised roughly $150 million in equity financing since 2017 and is advancing STX-1150 -- an epigenetic-silencing CRISPR candidate for cardiovascular disease -- through an Australian first-in-human trial, while disclosing only $49.7 million in cash and marketable securities against a $175.1 million accumulated deficit.

IPO
Scribe Therapeutics Files for $75M IPO to Test Early-Stage Biotech Appetite
Illustration for: Scribe Therapeutics Files for $75M IPO to Test Early-Stage Biotech Appetite
IPOUp to $75M IPO

Scribe Therapeutics Files for $75M IPO to Test Early-Stage Biotech Appetite

Scribe Therapeutics filed to raise up to $75 million in a Nasdaq IPO, becoming an early test of public-market appetite for Phase 1 biotechs -- its lead candidate, a CRISPR-based epigenetic therapy targeting PCSK9 to lower LDL cholesterol, is already in a.

Value Add Research

Related Companies

Scribe Therapeutics FAQ

Who founded Scribe Therapeutics?

Scribe Therapeutics was founded by CRISPR co-discoverer Jennifer Doudna and her UC Berkeley collaborators Benjamin Oakes, Brett Staahl and David Savage.[6]

Is Scribe Therapeutics a public company?

Scribe priced its IPO at $15 a share on July 23, 2026, the first IPO for a gene editing company since Metagenomi in February 2024.[3],[5],[1]

What does Scribe Therapeutics do?

Scribe Therapeutics is a clinical-stage biotech in Alameda, California, that engineers in vivo CRISPR technologies aimed at preventing disease.[1]

What is Scribe Therapeutics's market cap?

Scribe Therapeutics's market capitalization was $542.77M as of September 4, 2026, according to stockanalysis.com.

Who invested in Scribe Therapeutics?

Lead investors in Scribe Therapeutics's sourced funding rounds include Andreessen Horowitz. Per round: its October 2020 Series A was led by Andreessen Horowitz.

When was Scribe Therapeutics founded and where is it based?

Scribe Therapeutics was founded in 2018 and is headquartered in Alameda, California, USA, according to TechCrunch and Scribe Therapeutics.

References

researched 2026-10-23
  1. Yahoo Finance
  2. synbiobeta.com
  3. biopharmadive.com
  4. GEN
  5. biospace.com
  6. a16z.com
Sources & methodologyshow
Where these figures come from

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data ·